
Ascendis Pharma Reports First Quarter 2025 Financial Results
- Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025 - …